Daily Biotech Movers — 2026-09-29: Dispersion Collapsed Back to 4.70% as Breadth Worsened — and Not One of the Top Six Moved on Its Own Fresh Readout

Tuesday, September 29, 2026 did something Monday could not: it produced a normal-looking tape. Across 572 tracked public biotech and life-sciences companies, the cross-sectional standard deviation fell from Monday’s 8.98% to 4.70% — which is what happens when the single $90 equity that supplied most of Monday’s dispersion stops moving. But the normalisation arrived with a cost the dispersion number conceals: breadth got worse. 235 companies finished higher against 319 decliners, a decliner-to-advancer ratio of 1.36-to-1 — weaker than Monday’s 1.05-to-1 and the widest of the last four sessions. The median move was -0.51%, its worst reading since Thursday, and the mean -0.23%. 73 companies moved at least 5%, down from 81, and 95 were anomaly-flagged once volume-only spikes are counted, down from 101.

Those two facts point in opposite directions and both are true. Monday’s tape was violent and roughly balanced; Tuesday’s tape was calm and visibly tilted. The small-cap biotech proxy rose 0.15% against the broad healthcare proxy at -0.31% and the S&P 500 at -0.17% — a 0.46-point outperformance over broad healthcare that is a quarter of Monday’s 1.79 points and carries far less information. When the outliers stop being outliers, an index-level outperformance stops meaning anything in particular.

The more revealing fact about Tuesday is what the top six movers had in common. Not one of them moved on a fresh clinical readout of its own. The largest gain in the tracked universe was a commercial guidance raise — Iovance Biotherapeutics at +31.48%. The largest decline was a partner’s data failure — ClearPoint Neuro at -23.12%, driven by a Huntington’s disease dataset generated by a collaborating company, not by ClearPoint. The other four were a five-day-old regulatory milestone (Profusa, +34.32%), a prior-day pre-clinical release compounded by a same-day warrant financing (Silexion Therapeutics, +28.18%), a speculative unwind with no same-day disclosure whatsoever (Onconetix, -26.13%), and a balance-sheet repricing (Karyopharm Therapeutics, -25.54%). On the day dispersion collapsed toward normal, the leaderboard was assembled almost entirely from second-order effects.

The Distribution

Measure	September 29 reading	September 28 reading
Tracked / priced	572	572
Directional moves	554 (235 up, 319 down)	559 (273 up, 286 down)
Up / down ratio	1.36-to-1 decliners	1.05-to-1 decliners
Mean / median	-0.23% / -0.51%	-0.12% / -0.13%
Standard deviation	4.70%	8.98%
Average advancer / decliner	+2.99% / -2.61%	+3.12% / -3.20%
Price moves of at least 5%	73	81
Anomaly-flagged (incl. volume-only)	95	101
Stealth names (|move| < 3% on 3x+ volume)	4	0
Small-cap biotech proxy (XBI)	+0.15%	+1.04%
Broad healthcare proxy (XLV)	-0.31%	+0.33%

Three features matter. First, dispersion normalised while breadth deteriorated — the standard deviation halved and the decliner-to-advancer ratio widened from 1.05 to 1.36. That combination is the signature of a session where the outliers stopped being outliers, not of one where the middle improved. Second, both tails narrowed: the average advancer slipped from +3.12% to +2.99% and the average decliner contracted from -3.20% to -2.61%, so even the surviving extremes were less extreme than Monday’s. Third, the stealth set returned, with four names clearing a 3x volume filter while holding a move under 3% after Monday’s empty reading — quiet turnover is back on the board, and its return coincides with the disappearance of the price anomalies.

The sector table is a warning about averages pointing in both directions. On the surface, Genetics & Genomics led at +2.80% (n=7) — but the median in that bucket is -0.72%, and removing a single name, Nautilus Biotechnology at +22.97%, takes the seven-stock average to -0.56%. The winner’s circle was one stock wide. The same distortion runs at the bottom: Devices – Imaging at -4.78% (n=8, median -3.32%) is the worst bucket on the board, and removing ClearPoint Neuro at -23.12% lifts it to -2.16% — better, but still the second-weakest reading available, which tells you the weakness in imaging was genuine and merely concentrated in one name. The one bucket where average and median agree in the same direction is Non-Pharmaceutical Biotech at +1.59% (n=20, median +0.61%), and it is the cleanest broad signal on the board: a genuine, if modest, bid for platform and tools companies. Against it, the largest bucket in the universe, Small Molecule Pharma (n=149), sat at -0.75% with a median of -0.79% — and removing Karyopharm’s -25.54% print only lifts that to -0.58%, meaning the weakness there was broad rather than name-specific. Diagnostics (n=28) was second-worst at -2.08% on a -0.61% median, and Biologics (n=83) was essentially flat at -0.05% with a -0.63% median — which, once Iovance’s +31.48% is removed, becomes -0.43%. Two of the day’s six biggest movers were the entire difference between a flat sector and a negative one.

The 6 Classes of Mover Signal

1. Halt-release and reverse-split-adjacent mechanics. Present in both nano-cap winners, and it is the reason neither should be read as a fundamental repricing. Profusa (+34.32% on 3.00x) is a low-float equity that has absorbed a 1-for-4 reverse split and regained Nasdaq minimum-bid compliance only on September 15; its recorded 52-week high of $3,007.52 is a pre-split artifact, and the $1.58 low is the only meaningful boundary in the range column. Silexion Therapeutics (+28.18% on 20.15x) closed at $0.3184, roughly a third above its recorded 52-week low of $0.24. Both are sub-$3 decimals where percentage moves amplify small absolute changes; a +28% session in a $0.32 equity is not the same signal as a +28% session in a $32 one, and the taxonomy’s rule of thumb — always quote the absolute price so the reader can calibrate — applies to every name in this paragraph.

2. Single-stock clinical, regulatory or commercial catalyst. Present, and it produced the day’s largest print in its commercial form rather than its clinical one. Iovance Biotherapeutics (+31.48% on 5.22x) moved on a raised full-year revenue outlook attached to demand for its approved cell therapy, which is a fundamental repricing with an institutional footprint. The class also appears in a delayed form: Profusa’s September 24 disclosure of a positive notified-body decision on its quality-management certification is a genuine regulatory step, but it is five trading days old and the shares had already round-tripped on it. On the losing side, ClearPoint Neuro’s decline is a read-through to a partner’s disclosure rather than an event of its own — the same class, inverted.

3. Buyout and strategic capital. Absent from the leaderboard, with one caveat. Onconetix (-26.13%) is the target side of a live strategic transaction — an all-stock acquisition of Realbotix LLC, a humanoid-robotics business, that would hand the seller a 75–90% stake in the combined entity — but the stock appears in the taxonomy’s unwind form, not its announcement form. When a strategic transaction is announced, the acquiree’s paper typically reprices toward the deal; here the re-rating ran ahead of the deal and is now giving back. No new transaction was signed or terminated on Tuesday.

4. Sector rotation. Present but faint, and it ran the same direction as Monday at a fraction of the amplitude. XBI +0.15% against XLV -0.31% repeats Monday’s XBI +1.04% against XLV +0.33% in miniature, and the sector table agrees from the inside: the tools-and-platform bucket was the only group with a positive average and a positive median, while small-molecule pharma, the largest bucket, was negative on both. This is the fourth consecutive session in which capital has favoured the revenue-visible and platform-adjacent end of the complex over the clinical-stage middle — but at 0.46 points of relative performance, it is a lean, not a rotation.

5. Sell-the-news and prior-cycle profit-taking. Present, and it accounts for three of the six leaderboard names. Onconetix (-26.13%) gave back part of a +69.49% five-session run on 1.23x volume with no same-day news — the textbook unwind of a speculative rally whose catalyst belongs to a previous week. Profusa (+34.32%) is the same class moving in the opposite direction, a delayed continuation off its September 24 release. Silexion Therapeutics (+28.18%) blends the class with dilution mechanics: the pre-clinical narrative is one session old, while the financing that capped it is same-day. The tell across all three is the five-day column — PFSA -12.89%, SLXN -54.35%, ONCO +69.49% — which shows each name unwinding or continuing inside its own week rather than breaking out of it.

6. Stealth accumulation and distribution. Returned after Monday’s empty reading, and the four prints split across the two interpretations. Satellos Bioscience (-2.38% on 14.82x) is the largest multiple of the group on a real, if small, share count — a distribution signature on a name that has also slipped 4.0% over five sessions. Tectonic Therapeutic (-0.72% on 5.10x) and Unicycive Therapeutics (-1.94% on 3.01x) both traded flat-to-down on three-to-five times normal turnover after five-day moves of -11.7% and -2.7% respectively, which reads as holders exiting into a bid rather than as accumulation. Nexalin Technology (+1.16% on 4.70x) is the only one of the four with a flat five-day column (0.0%) and a slightly positive price, which makes it the most plausible accumulation candidate of the set. None of these four is a price signal; all four are next-session signals.

Top 3 Winners — What Drove Them

PFSA — Profusa — +34.32% on 3.00x volume

Profusa closed at $2.27 on 10,933,998 shares — 3.00x its 30-day average, against a $1.69 prior close, in a $1.63–$2.45 range, with five-day momentum of -12.89% and the close sitting about 44% above the recorded 52-week low of $1.58. Signal class: Class 2 regulatory step — processed by the tape as Class 1/5 mechanics. No fresh same-day catalyst — flagged. The most recent substantive release is the September 24 announcement that the company received a positive decision from GMED, the EU-designated notified body, on certification of its quality-management system to ISO 13485 — a prerequisite step on the path to CE marking for its Lumee Oxygen Platform, which the company expects in early October StockTitan — Profusa Gets Positive ISO 13485 Decision, CE Mark Pending; Market Chameleon — Profusa Highlights ISO 13485 Milestone; FinancialContent — Profusa Announces Significant Progress Towards Lumee Oxygen Platform CE Mark. The company was explicit at the time that the decision advances the platform toward CE marking and does not constitute it Yahoo Finance — Profusa ISO 13485 Certification Decision Advances Lumee Oxygen Platform. Tuesday’s session followed a -22.48% decline on Monday and a -28.05% decline on Friday, so the print is a rebound inside a round trip, on three times normal volume rather than ten — the profile of thin-order-book speculation ahead of an October certification date, not of institutions repricing new information.

IOVA — Iovance Biotherapeutics — +31.48% on 5.22x volume

Iovance closed at $14.45 on 78,122,621 shares — 5.22x its 30-day average, against a $10.99 prior close, in a $12.78–$15.30 range, with five-day momentum of +7.85% — and the close is 29% above the previously recorded 52-week high of $11.16, making this a new 52-week high on the highest volume of any advancer on the board. Signal class: Class 2 single-stock commercial catalyst — a guidance raise. Management lifted its full-year 2026 total revenue guidance to $410–420 million, citing stronger-than-expected U.S. demand for Amtagvi (lifileucel) and Proleukin RTTNews — Iovance Biotherapeutics Raises 2026 Revenue Guidance On Strong Amtagvi Demand; Yahoo Finance — IOVA Stock Hits Over 2-Year Highs: Why Iovance Raised Its FY2026 Outlook; Seeking Alpha — Iovance stock rises as analysts cheer new outlook. The raise is the cleanest kind of biotech catalyst because it is retrospective rather than prospective — it reports demand that has already been realised rather than a probability of future approval — and analysts published higher targets during the session as the launch-skepticism narrative that had capped the shares all year was repriced Cryptonomist — Iovance stock surges 33% after guidance hike; Timothy Sykes — Iovance Biotherapeutics Stock Draws Bullish Targets. With a five-day column of only +7.85% against a +31.48% day, the entire move was made in one session — the event signature, not the trend signature.

SLXN — Silexion Therapeutics — +28.18% on 20.15x volume

Silexion closed at $0.3184 on 255,847,818 shares — 20.15x its 30-day average, against a $0.2484 prior close, in a $0.29–$0.40 range, with five-day momentum of -54.35% and the close about 33% above the recorded 52-week low of $0.24. Signal class: Class 5 prior-cycle continuation compounded by same-day dilution. The narrative leg is one session old: on September 28 the company reported translational pre-clinical data showing that SIL204, its KRAS-targeting RNAi candidate, uses naturally circulating serum lipoproteins to enter KRAS-driven cancer cells and achieve dose-dependent knockdown of mutant KRAS, and the shares spiked after hours on that release Yahoo Finance — Silexion Therapeutics Reports Positive Preclinical Findings for SIL204; TipRanks — Silexion Highlights Positive Translational Data for RNAi Oncology; Benzinga — Silexion Therapeutics Stock Soars 61% After Hours. The financing leg is same-day and dilutive: the company entered an inducement offer under which holders of 3,216,928 existing warrants had their exercise price cut from $0.65 to $0.2603 in exchange for immediate cash exercise, with 6,433,856 new warrants issued in replacement Silexion Therapeutics — Announces Exercise of Warrants; TipRanks — Silexion Therapeutics Announces Warrant Inducement Financing Deal. A -54.35% five-day column against a +28.18% day, a $0.32 quote, and 256 million shares changing hands at an exercise price 18% below the close is what a nano-cap looks like when a data spike and a warrant-holder exit arrive in the same two sessions. The 20x volume ratio is the mechanism, not a confirmation of the science.

Top 3 Losers — What Drove Them

ONCO — Onconetix — -26.13% on 1.23x volume

Onconetix closed at $0.82 on 5,467,984 shares — 1.23x its 30-day average, against a $1.11 prior close, in a $0.72–$1.07 range, with five-day momentum of +69.49% and the close about 39% above the recorded 52-week low of $0.59. Signal class: Class 5 sell-the-news unwind — no fresh same-day catalyst — flagged. Nothing was disclosed on Tuesday and nothing has been disclosed since September 14, when the company reported up to $5 million of non-interest-bearing bridge financing to Realbotix LLC, the humanoid-robotics developer it has agreed to acquire Onconetix — News Releases; Nasdaq/RTTNews — Onconetix signs definitive share exchange agreement. The transaction in question is an all-stock acquisition of a humanoid-robotics developer that would leave the seller holding 75–90% of the combined entity — a fundamental change of business whose initial market reception was negative and whose subsequent rally, from $0.60 at the end of August to above $1.10, was speculative rather than fundamental AInvest — Onconetix Plunges on AI Robotics Acquisition. A -26.13% session on 1.23x volume — below the anomaly threshold on turnover, but flagged on price — after a +69.49% five-day run is the arithmetic of a momentum bid leaving: the seller did not need to arrive for the price to fall, the buyer simply stopped. This synthesis deliberately attaches no same-day catalyst to the move.

KPTI — Karyopharm Therapeutics — -25.54% on 1.45x volume

Karyopharm closed at $1.2062 on 1,865,961 shares — 1.45x its 30-day average, against a $1.62 prior close, in a $1.20–$1.62 range that printed a new 52-week low beneath the previously recorded $1.24 floor, with five-day momentum of -12.90% and the close 63% below the recorded 52-week high of $10.99. Signal class: capital-structure repricing — a balance-sheet event that has been public for two and a half weeks, not a fresh disclosure. The company’s September 11 Form 8-K is the binding document: Karyopharm missed a $15.8 million term-loan principal instalment due September 10 and its June 30 interest payments, expects to miss the September 30 interest payment, and disclosed that the resulting events of default and cross-defaults lift the applicable rate to 2.00% above the otherwise applicable margin SEC — Form 8-K, Karyopharm Therapeutics; FilingDiff — KPTI 8-K, September 11, 2026. The same filing states the company would be unable to continue as a going concern beyond October 15, 2026 without additional funding or a strategic alternative — a date now 16 days away FiercePharma — It’s crunch time for Karyopharm as company faces potential default. The commercial asset behind the deadline is real: Karyopharm markets XPOVIO (selinexor) and submitted a supplemental application to the FDA on August 31 seeking accelerated approval for selinexor plus ruxolitinib in myelofibrosis, with a priority-review request attached Karyopharm — Submits Supplemental New Drug Application for XPOVIO Plus Ruxolitinib in Myelofibrosis. That is precisely what makes the tape’s message legible: a company with a commercial product and a live regulatory filing traded down 25.54% on a solvency clock rather than an efficacy question. Layered on top is a separate Nasdaq minimum-bid deficiency: the shares must close at $1.00 or better for 10 consecutive business days, and a close at $1.21 holds that requirement by nine cents Investing.com — Karyopharm faces Nasdaq delisting over share price woes; Biotech Insider — Karyopharm Has a Month to Avert Default. The 1.45x volume is the most informative number in this paragraph: a -25.54% decline on turnover only 45% above normal is not a seller arriving in force. It is a thin bid stepping away from a company whose deadline is measured in days.

CLPT — ClearPoint Neuro — -23.12% on 4.66x volume

ClearPoint closed at $11.77 on 2,695,876 shares — 4.66x its 30-day average, against a $15.31 prior close, in an $11.60–$12.99 range, with five-day momentum of +9.59% and the close about 42% above the recorded 52-week low of $8.27. Signal class: Class 2 single-stock catalyst by read-through — the disclosure belongs to a partner. On Tuesday uniQure reported updated Phase I/II data for AMT-130 (ifezuntirgene inilparvovec), its one-time gene therapy for Huntington’s disease: at 48 months the high-dose cohort showed a 44% slowing of disease progression on the cUHDRS, a result that fell short of statistical significance and was less pronounced than the 36-month read a year earlier, sending uniQure’s shares down as much as 48–55% Reuters — UniQure plunges as Huntington’s trial data disappoints investors; FierceBiotech — uniQure stock crashes as Huntington’s gene therapy data weaken; Yahoo Finance — UniQure Says Additional AMT-130 Data Show Weaker Results at 4 Years. ClearPoint supplies the stereotactic navigation and drug-delivery platform used in the intracranial administration of precisely this class of therapy, so a weakening of the AMT-130 dataset removes visibility from one of its most-cited commercial pathways — and the shares had already absorbed a lowered full-year revenue outlook of $48–52 million against a widening loss profile earlier in the period Yahoo Finance — ClearPoint Neuro Shares Fall 24% Following uniQure AMT-130 Trial Update; AInvest — ClearPoint Neuro falls after partner uniQure trial setback; Finviz — same report. The 4.66x volume on a $11.77 mid-cap is institutional flow acting on a contagion read: the market repriced a delivery-platform supplier because its customer’s data weakened, in one session, on the heaviest turnover of any decliner on the board. Note the +9.59% five-day column — this is not a falling knife being caught; it is a new high giving way.

The Cross-Cutting Pattern

The pattern is the disappearance of the outlier and the widening of the middle — and the six leaderboard names are the proof. Monday’s standard deviation of 8.98% was the arithmetic of one stock; Tuesday’s 4.70% is the arithmetic of none. What replaced the outlier was not equilibrium but tilt: 319 decliners against 235 advancers, a -0.51% median, and an anomaly count that fell for the second consecutive session. When a market’s dispersion normalises while its breadth worsens, the honest reading is that the previous session’s violence was idiosyncratic and the current session’s weakness is structural. That is what Tuesday looks like.

The second theme is that the market paid for commercial evidence and discounted everything else — including its own events. Iovance’s guidance raise was the only name in the top six to be repriced on retrospective facts: demand already recorded, revenue already recognisable, a 52-week high on 5.22x volume with a five-day column of +7.85%. ClearPoint fell on someone else’s prospective disappointment. Profusa rose on a five-day-old regulatory step that has not yet produced a certification. Silexion rose on a one-day-old pre-clinical mechanism paper while simultaneously issuing replacement warrants at a strike below the market. Onconetix fell on nothing. Karyopharm fell on a two-and-a-half-week-old default disclosure whose next milestone — a September 30 interest payment, and a going-concern date of October 15 — is a calendar fact rather than a news event. Zero of the six were repriced by a fresh clinical readout of their own. In a session where the average decliner contracted and the median fell, the market’s appetite went to balance-sheet visibility and approved-product economics, and the clinical-stage middle paid for it.

The third theme is the asymmetry between volume and reason. The three heaviest volume ratios in the top six — Silexion at 20.15x, ClearPoint at 4.66x, Profusa at 3.00x — attach to three very different stories, and only one of them is a fundamental repricing. The Karyopharm print at 1.45x is the day’s most instructive number precisely because it is the smallest: a -25.54% move on near-normal turnover is a bid being withdrawn from a company with a 16-day solvency horizon and a listing requirement it holds by nine cents. Meanwhile the day’s heaviest multiple on the entire board belongs to KALA BIO at 52.56x on a +11.79% close — an 8.4-point price move on 52 times normal volume, which is a repo or a halt-adjacent technical print rather than a catalyst anyone published. The volume column told three stories on Tuesday: conviction, contagion, and mechanics.

The 5 Data Points That Matter

1. Percentage change versus the tape. With a -0.51% median, the six leaderboard names span a 34-to-26-point divergence — modest by Monday’s standards, when the spread reached 178 points. The two names that decoupled hardest from their own bucket are the same two that distort it: Profusa +34.32% in a Northern California bucket of three companies, and ClearPoint Neuro -23.12% against a Devices – Imaging bucket that reads -4.78% including it and -2.16% without it. The cleanest single-name reads are Iovance +31.48% and Karyopharm -25.54%, because neither carries a sector claim — they are company-specific events inside flat-to-negative buckets of 83 and 149 names.

2. Volume ratio. The heaviest ratios on the board are KALA BIO at 52.56x, Nautilus Biotechnology at 21.11x and Silexion at 20.15x — and only the last of those belongs to the leaderboard. Volume confirming a fundamental repricing appears exactly twice in the top six: Iovance at 5.22x on 78.1 million shares, and ClearPoint at 4.66x on 2.7 million shares. Volume absent from a large move appears the same number of times: Onconetix at 1.23x and Karyopharm at 1.45x, both down more than 25% on turnover at or barely above normal. That pairing is the single most useful diagnostic on the page today — when the biggest declines have the smallest volume ratios, the move is about the absence of a bid, not the arrival of a seller.

3. Five-day momentum. This column separates an event from a trend, and on Tuesday it separates almost every name on the board. Iovance at +7.85% against a +31.48% day is a fresh event out of a flat week. ClearPoint at +9.59% against -23.12% is a name at a new high one session before it broke. Silexion at -54.35% and Profusa at -12.89% are both unwinding or rebounding inside their own week. And Onconetix at +69.49% against -26.13% is the purest prior-cycle signature available: a five-session advance being handed back one day at a time, with the majority still ahead of the unwind if it continues at Tuesday’s pace.

4. Position in range and absolute price. Tuesday’s leaderboard spans two price regimes. Iovance at $14.45 printed a new 52-week high, CLPT at $11.77 sits 42% above its low but has just lost a fifth of its value, and Karyopharm at $1.2062 printed a new 52-week low beneath its previous $1.24 floor while holding a Nasdaq requirement by nine cents. Against them, Silexion at $0.3184, Onconetix at $0.82 and Profusa at $2.27 are decimal equities whose percentage moves are arithmetic artifacts of a small denominator as much as statements about value. The range column is where the day’s split is clearest: the winners are at highs or rebounds, the losers are at lows, and the three names that matter least are the three that traded most.

5. Cash and dilution context. This is the differentiator, and it organises the entire board. Karyopharm has missed a $15.8 million principal instalment, expects to miss September 30 interest, and has told investors it cannot continue as a going concern past October 15 without funding — a solvency clock, not a sentiment problem. Silexion repriced 3.2 million warrants down to $0.2603 and issued 6.4 million more to induce exercise, converting a data rally into share supply. Onconetix is issuing stock to a robotics seller that will own 75–90% of it, which makes the equity a claim on a transaction rather than on a business. Profusa is a no-revenue device company whose certified milestone is a certification step, not a commercial one. Against all four, Iovance is funded by approved-product demand that management just raised guidance on, and ClearPoint is funded by an installed base of surgical navigation systems whose next read is a partner’s trial, not its own. Capital released versus capital required is the organising asymmetry of the day — and on Tuesday, the market paid for the first and charged for the second, exactly as it did on Monday.

The five-point summary: read Iovance as a genuine commercial repricing — a guidance raise on realised demand, a new 52-week high on the highest volume of any advancer; read ClearPoint as contagion from a partner’s 48-month dataset, on the heaviest volume of any decliner, one session after hitting a high; read Profusa as a five-day-old certification step being speculated on in a $2.27 low-float equity; read Silexion as a one-day-old pre-clinical readout being financed away by warrant holders at a strike 18% below the close; read Onconetix as a +69.49% five-session rally unwinding on 1.23x volume with no news at all; and read Karyopharm as a solvency clock and a listing requirement converging on a -25.54% print that traded on 1.45x normal turnover.

What This Synthesis Will and Won’t Tell You

This is a one-day reading and should be read as one. It tells you what moved and why: the 95 anomaly-flagged names, the six data-defined top movers, the signal class behind each, and the cross-cutting pattern — dispersion halving while breadth widened to 1.36-to-1 decliners, a sector leader that is one stock wide, and a top six in which not a single name was repriced by a clinical readout of its own. It does not tell you what happens next: whether Iovance’s raised guidance is confirmed by the next quarterly print or was a pull-forward; whether ClearPoint loses follow-on platform demand because a partner’s therapy weakened or simply absorbs one session of contagion; whether Karyopharm pays the September 30 interest, secures funding before October 15, or takes the strategic-alternative route; whether Silexion’s warrant supply caps the pre-clinical narrative for the rest of the week; whether Profusa converts its certification step into an actual CE marking in October; or whether Onconetix’s unwind has further to run given that two-thirds of the five-session advance remains above Tuesday’s close.

The honest limits are three. First, the catalyst investigation covers the six data-defined top movers only — the rest of the anomaly board, including KALA BIO +11.79% on 52.56x, Nautilus Biotechnology +22.97% on 21.11x, Aldeyra Therapeutics +13.79% on 8.26x, Lexeo Therapeutics +8.92% on 6.72x, Invivyd -10.52% on 6.00x, Ginkgo Bioworks +14.44% on 3.19x, Summit Therapeutics +5.88% on 4.37x and Recursion Pharmaceuticals +8.92%, carries stories that are noted but not investigated here. Second, two of the six leaderboard names had no clean same-day catalyst — Profusa and Onconetix are labelled mechanical or prior-cycle rather than assigned narratives they do not have, and both remain in the profile list because they are part of the day’s leaderboard regardless of whether they had news. Third, the sector averages are not robust to single observations: the headline sector leader collapses from +2.80% to -0.56% without one name, the worst bucket improves from -4.78% to -2.16% without one name, and Biologics moves from -0.05% to -0.43% without Iovance. Any reader who quotes a sector average from this session without checking the median is quoting a company, not a group.

---

This is editorial analysis, not investment advice. Single-day returns reflect regular-session closing prices on 2026-09-29 and will change with market conditions, clinical readouts, financing terms, and regulatory events. Microcap and clinical-stage names can experience rapid reversals; several of the names discussed here trade below $1.00, carry going-concern or listing-compliance disclosures, or have pending capital events, and readers should review the underlying filings before drawing conclusions about momentum durability.

Generated 2026-09-29 PT (post-market, after the 4 PM ET close). Market data compiled from public quote and historical market-data feeds; sector categorisation from public company filings and listings; company backgrounds compiled from public investor disclosures and press releases. For the prior synthesis, see Daily Biotech Movers — 2026-09-28.